Business
Nuvectis Pharma Recaps Oral Presentation Highlights for NXP800 at the 2022 American Association for Cancer Research (AACR) Conference
Fort Lee, NJ, April 11, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT), (“Nuvectis” or the “Company”), a biopharmaceutical company focused on
About this update from Nuvectis Pharma, Inc.
[{"type":"text","content":"Fort Lee, NJ, April 11, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT), (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, today provided highlights from the oral presentation of NXP800 that took place yesterday at the American Association for Cancer Research (“AACR”) Conference in New Orleans. The presentor, Prof. Paul Workman, is head of the NXP800 program at, and former CEO of, The Institute of Cancer Research, London, UK. “We are very pleased to have been given the opportunity to showcase NXP800 at the New Drugs On The Horizon session of the 2022 Annual AACR Meeting,\" said Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis. Mr. Bentsur continued, “The oral presentation of NXP800, our clinical stage Heat Shock Factor 1 (“HSF1”) pathway inhibitor, provided important insights into over a decade-long program of focused and rationally-designed discovery and optimization work that resulted in the selection of NXP800 as the clinical candidate. The presentation also provided robust proof-of-concept for the selection of ovarian clear cell carcinoma (“OCCC”) and endometrioid ovarian carcinoma as the two lead indications for clinical development, as well as for the potential utility of ARID1a as a patient selection marker in these two diseases and additional solid tumors. We continue to advance the clinical program of HSF1 and plan to share clinical data from the Phase 1 study later this year. In addition, there is a broad range of preclinical studies underway designed to identify additional target tumor types for clinical trials.\" NXP800 Oral Presentation Key Highlights Multiple independent publications implicate HSF1 in various cancersNXP800 is the clinical candidate that emerged from an extensive discovery and optimization research program conducted at The Institute of Cancer Research in London, EnglandPharmacodynamic markers for NXP800 activity identified HSF1 gene cluster is downregulatedCHAC1, which encodes the protein that degrades glutathione, is activated ARID1a is a biomarker that predicted sensitivity to treatment with NXP800 In-vivo xenograft models of OCCC and endometrioid ovarian cancer in which ARID1a was mutated were more sensitive to treatment with NXP800Large-scale screening (S...